The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Clinical Activity of Rucaparib in Patients With Ovarian Cancer

Rebecca Kristeleit, BSc, PhD
Published Online: 7:02 PM, Tue October 11, 2016


Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the clinical activity and efficacy of rucaparib in patients with high-grade ovarian carcinoma and a BRCA mutation during an interview at the 2016 ESMO Congress.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.